FINWIRES · TerminalLIVE
FINWIRES

Research Alert: Garmin Posts Q1 Earnings Beat And In-line Revenue

作者

-- CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:

GRMN delivered exceptional Q1 2026 results with record revenue of $1.75B (+14% Y/Y) and pro forma EPS of $2.08 (+29% Y/Y), demonstrating strong operational leverage as operating margins expanded 290 bps to 24.6%. The quarter showcased significant margin expansion with gross margins improving 180 bps to 59.4% while operating income surged 30% to $431.7M. The Fitness segment led performance with exceptional 42% growth to $546.8M, while Aviation (+18%) and Marine (+11%) maintained strong double-digit trajectories, though Outdoor declined 5% against tough comparisons. Auto OEM realized 1% Y/Y growth. We believe the quarter demonstrates GRMN's ability to drive profitability growth significantly exceeding top-line expansion across its diversified portfolio. The company's robust $4.31B cash position and $469.4M free cash flow generation provide strategic flexibility for continued innovation and capital returns. Management maintained its confident full-year guidance of $7.9B revenue and $9.35 pro forma EPS for 2026.

相关文章

Australia

Ryde与VinaTaxi签署谅解备忘录,探索越南市场机遇

Ryde集团(RYDE)周三宣布,已与VinaTaxi签署谅解备忘录,共同探索在越南的战略合作机会。 该公司表示,合作探索的领域包括在VinaTaxi的出租车车队中部署Ryde的平台,以及开发电动摩托车出行生态系统。Price: $1.20, Change: $+0.02, Percent Change: +1.61%

$RYDE
Australia

Emergent BioSolutions 签署价值 5000 万美元的合同,为 SAB Biotherapeutics 的领先项目提供支持

Emergent BioSolutions (EBS) 周三宣布,已与 SAB Biotherapeutics (SABS) 签署一项价值 5000 万美元的多年期协议,以推进 SAB-142 的临床开发,该药物用于治疗自身免疫性 1 型糖尿病。 根据协议,其中 3600 万美元的款项取决于未来的监管审批和后续里程碑的达成情况。 Emergent BioSolutions 表示,将提供符合现行良好生产规范 (cGMP) 的端到端开发和生产服务。Price: $8.17, Change: $-0.07, Percent Change: -0.79%

$EBS$SABS
Australia

Immunome公司提交了基于3期临床试验数据的Varegacestat新药申请。

Immunome(IMNM)周三宣布,已向美国食品药品监督管理局(FDA)提交了新药申请,申请上市的药物为varegacestat,一种用于治疗成人纤维瘤的在研口服药物。 该公司表示,此次申请基于积极的3期RINGSIDE试验结果,结果显示与安慰剂相比,varegacestat显著改善了患者的无进展生存期,降低了84%的疾病进展或死亡风险,客观缓解率达到56%。 该公司补充说,试验的详细数据将在2026年美国临床肿瘤学会(ASCO)年会上公布。 Immunome股价周三下跌2.7%。Price: $23.18, Change: $-0.53, Percent Change: -2.24%

$IMNM